PMCB 10-Q
PharmaCyte Biotech, Inc. (PMCB)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
or
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from __________ to __________
Commission file number
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices)
(
(Registrant’s telephone number, including area code)
| Securities registered pursuant to Section 12(b) of the Act: | ||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The | ||||
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | |
| Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of March 12, 2026, the registrant had outstanding shares of common stock, with a par value of $0.0001 per share.
PHARMACYTE BIOTECH, INC.
INDEX TO QUARTERLY REPORT ON FORM 10-Q
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026
| 2 |
PART I – FINANCIAL INFORMATION
Item 1. Financial Information.
PHARMACYTE BIOTECH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| (Unaudited) | ||||||||
| January
31, 2026 | April
30, 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Marketable equity securities | ||||||||
| Warrant asset – QCLS - current | ||||||||
| Convertible Note receivable – Femasys - current | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Other assets: | ||||||||
| Intangible asset | ||||||||
| Investment in preferred stock – QCLS | ||||||||
| Warrant asset – QCLS – non current | ||||||||
| Warrant asset – Femasys | ||||||||
| Other assets | ||||||||
| Total other assets | ||||||||
| Total Assets | $ | $ | ||||||
| LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Accrued Series C dividends | ||||||||
| Total current liabilities | ||||||||
| Other liabilities: | ||||||||
| Long-term portion of accrued expenses | ||||||||
| Warrant liabilities | ||||||||
| Derivative liabilities | ||||||||
| Total other liabilities | ||||||||
| Total Liabilities | ||||||||
| Commitments and Contingencies (Note 8) | ||||||||
| Temporary Equity: | ||||||||
| Series B convertible preferred
stock: authorized shares, $ par value and $ | ||||||||
| Series C convertible preferred
stock: authorized shares, $ par value and $ | ||||||||
| Contingently redeemable warrants | ||||||||
| Total temporary equity | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, authorized | ||||||||
| Series A preferred stock: authorized share, $ par value and shares issued and outstanding as of January 31, 2026 and April 30, 2025 | ||||||||
| Common stock: authorized shares, $ par value; and shares issued and and shares outstanding as of January 31, 2026 and April 30, 2025, respectively. | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Treasury stock, at cost, and shares as of January 31, 2026, and April 30, 2025, respectively. | ( | ) | ( | ) | ||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total Liabilities, Temporary Equity and Stockholders’ Equity | $ | $ | ||||||
See accompanying Notes to Condensed Consolidated Financial Statements.
| 3 |
PHARMACYTE BIOTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
| Three Months Ended January 31, | Nine Months Ended January 31, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development costs | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expenses): | ||||||||||||||||
| Interest income | ||||||||||||||||
| Change in fair value of warrant liability | ( | ) | ||||||||||||||
| Change in fair value of derivative liability | ||||||||||||||||
| Change in fair value of convertible note receivable - Femasys | ( | ) | ||||||||||||||
| Change in fair value of warrant asset - Femasys | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Change in fair value of investment - QCLS | ( | ) | ( | ) | ( | ) | ||||||||||
| Change in fair value of warrants - QCLS | ( | ) | ( | ) | ( | ) | ||||||||||
| Gain on legal settlement – re-fair value of warrants | ||||||||||||||||
| Gain on related party investment - QCLS | ||||||||||||||||
| Issuance costs – Series C convertible preferred stock and warrants | ( | ) | ||||||||||||||
| Loss on issuance of Series C convertible preferred stock | ( | ) | ||||||||||||||
| Unrealized loss on marketable securities | ( | ) | ( | ) | ||||||||||||
| Other expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other income and (expense), net | ( | ) | ( | ) | ||||||||||||
| Net income (loss) | ( | ) | ( | ) | ||||||||||||
| Preferred stock dividends | ( | ) | ( | ) | ( | ) | ||||||||||
| Preferred stock accretion | ( | ) | ( | ) | ( | ) | ||||||||||
| Net income (loss) attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||
| Basic and diluted income (loss) per share attributable to common stockholders | $ | ) | $ | ) | $ | ) | $ | |||||||||
| Weighted average shares outstanding basic and diluted | ||||||||||||||||
See accompanying Notes to Condensed Consolidated Financial Statements.
| 4 |
PHARMACYTE BIOTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
Three Months Ended January 31, | Nine Months Ended January 31, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation | ( | ) | ( | ) | ||||||||||||
| Other comprehensive income (loss) | ( | ) | ( | ) | ||||||||||||
| Comprehensive income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||
See accompanying Notes to Condensed Consolidated Financial Statements.
| 5 |
PHARMACYTE BIOTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY
THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND 2025
(UNAUDITED)
| Preferred Stock Series B | Preferred Stock Series C | Contingently Redeemable Warrants | Common Stock | Additional Paid-in | Treasury Stock | Accumulated | Accumulated Other Comprehensive | Total Stockholders’ | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Loss | Equity | ||||||||||||||||||||||||||||||||||||
| Balance, April 30, 2024 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Stock-based compensation options | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Preferred stock accretion | – | – | – | ( | ) | – | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Series B preferred stock redemption | ( | ) | ( | ) | – | – | – | |||||||||||||||||||||||||||||||||||||||||
| Series B preferred stock subject to redemption | ( | ) | ( | ) | – | – | – | |||||||||||||||||||||||||||||||||||||||||
| Preferred stock dividends | – | – | – | ( | ) | – | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Net income | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Repurchase of common stock | – | – | – | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Balance, July 31, 2024 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Fractional shares adjustment | – | – | – | |||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation options | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Preferred stock accretion | – | – | – | ( | ) | – | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Series B preferred stock redemption | ( | ) | ( | ) | – | – | – | |||||||||||||||||||||||||||||||||||||||||
| Series B preferred stock subject to redemption | ( | ) | ( | ) | – | – | – | |||||||||||||||||||||||||||||||||||||||||
| Preferred stock dividends | – | – | – | ( | ) | – | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Repurchase of common stock | – | – | – | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Balance, October 31, 2024 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation options | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | – | – | – | – | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Repurchase of common stock | – | – | – | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Balance, January 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
(continued)
| 6 |
| Preferred Stock Series B | Preferred Stock Series C | Contingently Redeemable Warrants | Common Stock | Additional Paid-in | Treasury Stock | Accumulated | Accumulated Other Comprehensive | Total Stockholders’ | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Loss | Equity | ||||||||||||||||||||||||||||||||||||
| Balance, April 30, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||||||||||
| Stock-based compensation options | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Net income | – | – | – | – | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Balance, July 31, 2025 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation options | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series C preferred stock and warrants, net of transaction costs | – | – | – | |||||||||||||||||||||||||||||||||||||||||||||
| Series C Preferred stock accretion | – | – | – | ( | ) | – | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Series C preferred stock dividend subject to settlement | – | – | ( | ) | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Series C preferred stock dividends accrual | – | – | – | ( | ) | – | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | – | – | – | – | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Balance, October 31, 2025 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation options | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Stock issued upon vesting of restricted stock units | – | – | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
| Stock issued for warrant exercises | – | – | – | |||||||||||||||||||||||||||||||||||||||||||||
| Preferred stock accretion | – | – | ( | ) | – | ( | ) | |||||||||||||||||||||||||||||||||||||||||
| Series C preferred stock redeemed | – | ( | ) | ( | ) | – | ||||||||||||||||||||||||||||||||||||||||||
| Series C preferred stock subject to settlement | – | – | ( | ) | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Preferred stock dividends | – | – | – | ( | ) | – | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Net income | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Repurchase of common stock | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||||
| Balance, January 31, 2026 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||
See accompanying Notes to Condensed Consolidated Financial Statements.
| 7 |
PHARMACYTE BIOTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| Nine Months Ended January 31, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income (loss) | $ | ( | ) | $ | ||||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||||
| Gain on related party investment – QCLS | ( | ) | ( | ) | ||||
| Issuance costs – Series C preferred stock and warrants | ||||||||
| Loss on issuance of Series C preferred stock | ||||||||
| Gain on re-fair value of warrants | ( | ) | ||||||
| Non-cash interest income | ( | ) | ( | ) | ||||
| Stock issued for compensation - RSUs | ||||||||
| Stock-based compensation - options | ||||||||
| Unrealized loss on marketable equity securities | ( | ) | ||||||
| Change in fair value of warrant liabilities | ( | ) | ||||||
| Change in fair value of derivative liability | ( | ) | ( | ) | ||||
| Change in fair value of convertible note receivable - Femasys | ( | ) | ( | ) | ||||
| Change in fair value of warrant asset – Femasys | ||||||||
| Change in fair value of investment – QCLS | ||||||||
| Change in fair value of warrants - QCLS | ( | ) | ||||||
| Change in assets and liabilities: | ||||||||
| Decrease in prepaid expenses and other current assets | ||||||||
| Increase in accounts payable | ||||||||
| Decrease in accrued expenses | ( | ) | ( | ) | ||||
| Net cash and cash equivalents used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Proceeds from investment - note receivable | ||||||||
| Investment in preferred stock and warrants in QCLS | ( | ) | ( | ) | ||||
| Net cash and cash equivalents provided by (used in) investing activities | ( | ) | ||||||
| Cash flows from financing activities: | ||||||||
| Repurchase of common stock, net | ( | ) | ( | ) | ||||
| Redemption of preferred stock | ( | ) | ||||||
| Net proceeds from issuance of Series C convertible preferred stock | ||||||||
| Net proceeds from exercises of warrants | ||||||||
| Payment of Series C convertible preferred stock dividends | ( | ) | ||||||
| Net cash and cash equivalents provided by (used in) financing activities | ( | ) | ||||||
| Effect of currency rate exchange on cash and cash equivalents | ( | ) | ||||||
| Net increase (decrease) in cash and cash equivalents | ( | ) | ||||||
| Cash and cash equivalents at beginning of the period | ||||||||
| Cash and cash equivalents at end of the period | $ | $ | ||||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Reclassification of Series B Convertible Preferred Stock and dividends to current liability | $ | $ | ||||||
| Accretion of discounts to redemption value of Series B Preferred Stock | $ | $ | ||||||
| Accrual of Series C Convertible Preferred Stock dividends | $ | $ | ||||||
| Accrual of Series C Convertible Preferred Stock issuance costs | $ | $ | ||||||
| Accretion of discounts to redemption value of Series C Preferred Stock | $ | $ | ||||||
| Initial fair value of investment in QCLS Series H preferred shares | $ | $ | ||||||
| Initial fair value of investment in QCLS Series H warrants | $ | $ | ||||||
| Non-cash derivative liability at initial fair value | $ | $ | ||||||
| Non-cash warrant liability at initial fair value | $ | $ | ||||||
| Non-cash redemption of Series C convertible preferred stock | $ | $ | ||||||
| Change in fair value associated warrant exercises | $ | $ | ||||||
| Fair value of contingently redeemable placement agent warrants | $ | $ | ||||||
| Excise tax accrued on repurchase of common stock | $ | $ | ||||||
See accompanying Notes to Condensed Consolidated Financial Statements.
| 8 |
PHARMACYTE BIOTECH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 – NATURE OF BUSINESS
PharmaCyte Biotech, Inc. (the “Company”) is a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (“LAPC”) will be developed. The current generation of the Company’s product candidate is referred to as “CypCaps™.”
The Company is a Nevada corporation incorporated in 1996. In 2013, the Company restructured its operations to focus on biotechnology. The Company acquired licenses from SG Austria Pte. Ltd., a Singapore corporation (“SG Austria”) and its wholly owned subsidiary, Austrianova Singapore Pte. Ltd., a Singapore corporation (“Austrianova Singapore”) using the Cell-in-the-Box technology to treat cancer. The restructuring resulted in the Company focusing all its efforts upon the development of a novel, effective and safe way to treat cancer. In January 2015, the Company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business. In October 2021, the Company moved its headquarters from Laguna Hills, California to Las Vegas, Nevada.
On September 1, 2020, the Company submitted an Investigational New Drug Application (“IND”) to the U.S. Food and Drug Administration (“FDA”) for a planned clinical trial in locally advanced pancreatic cancer (“LAPC”). On October 1, 2020, the Company received notice from the FDA that it had placed the IND on clinical hold. On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical hold and specific guidance on what the Company must do to have the clinical hold lifted.
To lift the clinical hold, the FDA informed the Company that it needs to conduct several additional preclinical studies. The FDA also requested additional information regarding several topics, including DNA sequencing data, manufacturing information and product release specifications. The Company has been in the process of conducting these studies and gathering additional information to submit to the FDA. See “Investigational New Drug Application and Clinical Hold” below.
On August 15, 2022, the Company entered into a Cooperation Agreement (“Cooperation Agreement”) with Iroquois Master Fund Ltd. and its affiliates, pursuant to which the Company elected a reconstituted Board of Directors (the “Board”). The Board has formed a Business Review Committee to evaluate, investigate and review the Company’s business, affairs, strategy, management and operations and in its sole discretion to make recommendations to the Company’s management and Board with respect thereto. The Business Review Committee is also reviewing many of the risks relative to the Company’s business. In addition, the Board is reviewing the Company’s development programs and its relationship with SG Austria, including that all licensed patents have expired, that know-how relating to the Company’s Cell-in-a-Box® technology solely resides with SG Austria, and that the incentives of SG Austria and its management may not be currently aligned with those of the Company. The Board has curtailed spending on the Company’s programs, including pre-clinical and clinical activities, until the review by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented. The Business Review Committee’s recommendations will include potentially seeking a new framework for the Company’s relationship with SG Austria and its subsidiaries. In the event the Company is unsuccessful in seeking an acceptable new framework, the Company will reevaluate whether it should continue those programs which are dependent on SG Austria, including its development programs for LAPC. The issues involving SG Austria have delayed the Company’s timeline for addressing the FDA clinical hold for its planned clinical trial in LAPC and could result in other delays or termination of the development activities. In addition, the curtailment of spending on the Company’s programs pending the review by the Business Review Committee and the Board may cause additional delays.
The Cell-in-a-Box® encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish. They are protected from environmental challenges, such as the sheer forces associated with bioreactors and passage through catheters and needles, which the Company believes enables greater cell growth and production of the active molecules. The capsules are largely composed of cellulose (cotton) and are bioinert.
| 9 |
The Company has been developing therapies for pancreatic solid cancerous tumors by using genetically engineered live human cells that it believes are capable of converting a cancer prodrug into its cancer-killing form. The Company encapsulates those cells using the Cell-in-a-Box® technology and places those capsules in the body as close as possible to the tumor. In this way, the Company believes that when a cancer prodrug is administered to a patient with a particular type of cancer that may be affected by the prodrug, the killing of the patient’s cancerous tumor may be optimized.
Until the review by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented, spending on the Company’s programs has been curtailed.
Investigational New Drug Application and Clinical Hold
On September 1, 2020, the Company submitted an IND to the FDA for a planned clinical trial in LAPC. On October 1, 2020, the Company received notice from the FDA that it had placed the Company’s IND on clinical hold. On October 30, 2020, the FDA sent the Company a letter setting forth the reasons for the clinical hold and providing specific guidance on what the Company must do to have the clinical hold lifted.
In order to address the clinical hold, the FDA requested that the Company:
| · | Provide additional sequencing data and genetic stability studies; | |
| · | Conduct a stability study on the Company’s final formulated product candidate as well as the cells from the Company’s Master Cell Bank; | |
| · | Evaluate the compatibility of the delivery devices (the prefilled syringe and the microcatheter used to implant the CypCaps™) with the Company’s product candidate for pancreatic cancer; | |
| · | Provide additional detailed description of the manufacturing process of the Company’s product candidate for pancreatic cancer; | |
| · | Provide additional product release specifications for the Company’s encapsulated cells; | |
| · | Demonstrate comparability between the 1st and 2nd generation of the Company’s product candidate for pancreatic cancer and ensure adequate and consistent product performance and safety between the two generations; | |
| · | Conduct a biocompatibility assessment using the Company’s capsules material; | |
| · | Address specified insufficiencies in the Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File; | |
| · | Conduct an additional nonclinical study in a large animal (such as a pig) to assess the safety, activity, and distribution of the product candidate for pancreatic cancer; and | |
| · | Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold and remove any statements not supported by the data the Company generated. |
| 10 |
The FDA also requested that the Company address the following issues as an amendment to the Company’s IND:
| · | Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency; | |
| · | Perform qualification studies for the drug filling step to ensure that the Company’s product candidate for pancreatic cancer remains sterile and stable during the filling process; | |
| · | Submit an updated batch analysis for the Company’s product candidate for the specific lot that will be used for manufacturing all future product candidates; | |
| · | Provide additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays; | |
| · | Provide a few examples of common microcatheters that fit the specifications in the Company’s Angiography Procedure Manual; | |
| · | Clarify the language in the Company’s Pharmacy Manual regarding proper use of the syringe fill with the Company’s product candidate for pancreatic cancer; and | |
| · | Provide a discussion with data for trial of the potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in the Company’s study population. |
The Company assembled a scientific and regulatory team of experts to address the FDA requests. Through January 31, 2026, the Company’s scientific consultants have been in active dialog with the FDA. The Company received communications from the FDA and responded, including the submission of the updated drug master file. The FDA accepted the updated master drug file and cleared many of the clinical hold items. The Company believes that the technology upon which the LAPC treatment will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans. The Company’s position is that the data available from these human clinical trials supersedes large animal study data, making the study unnecessary. The treatment may not be a treatment of pancreatic cancer, but a method of improving and possibly enabling complete surgical resection of the tumor. The Company is waiting for the FDA’s responses and hopes the FDA will accept that the LAPC treatment now meets manufacturing standard requirements, which have significantly improved since the clinical hold was first placed. The FDA may require additional preclinical studies when the meeting takes place. The Company is in ongoing dialogue with SG Austria to prepare for the next steps, including the preparation of the syringes filled with the latest generation of CypCaps™ with the working cell material.
NOTE 2 – LIQUIDITY AND OTHER UNCERTAINTIES
As of January 31, 2026, the Company had approximately $20.2 million in cash and cash equivalents as compared to approximately $15.2 million at April 30, 2025. The Company expects that its current cash and cash equivalents of approximately $19 million, as of the filing of this Quarterly Report on Form 10-Q, will be sufficient to support its projected operating requirements and financial commitments for at least the next twelve months from the date of this Quarterly Report.
In August 2025, the Company entered into a securities
purchase agreement pursuant to which it agreed to sell to investors in a private placement an aggregate of shares of the Company’s
newly designated Series C convertible preferred stock with a stated value of $1,000 per share and warrants to purchase up to
In September 2025, the Company entered into a
securities purchase agreement pursuant to which it agreed to purchase in a private placement QCLS Series H Preferred Stock (as defined
herein) initially convertible into shares, subject to adjustment of QCLS (as defined herein) common stock and warrants for an
aggregate purchase price of $
| 11 |
The Company expects to need additional capital in order to complete a clinical trial for the treatment of pancreatic cancer. If any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital is not assured and, if not achieved on a timely basis, will likely have a material adverse effect on the Company’s business, financial condition and results of operations.
The Company operates in an industry that is subject to rapid technological change, competition and government regulation. The Company’s operations are subject to significant risk and uncertainties including financial operational, technological, regulatory, and other risks. Such factors, include but not limited to, results of clinical testing and trial activities, the ability to obtain regulatory approval, the supply of needed materials, the ability to obtain manufacturing and the ability to raise capital to achieve strategic objectives.
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation and Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and the rules and regulation of the United States Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair statement of the unaudited condensed consolidated financial statements of the Company as of January 31, 2026 and for the three and nine months then ended. The results of operations for the three and nine months ended January 31, 2026 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of April 30, 2025 and for the year then ended which are included in the Company’s Annual Report on Form 10- K, filed with the SEC on August 11, 2025.
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through three wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; (ii) PharmaCyte Biotech Australia Pty. Ltd.; and (iii) Viridis Biotech, Inc. and are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and the Rules and Regulations of the Commission. Upon consolidation, intercompany balances and transactions are eliminated.
Use of Estimates in the Preparation of Financial Statements
The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s unaudited condensed consolidated financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company’s condensed consolidated financial position and results of operations. The Company’s most significant estimates and assumptions are the assessment of the fair value of long-lived assets, fair value measurements of investments, the valuation of warrants and derivative liabilities, and the measurement of stock-based compensation.
| 12 |
Reclassification
Certain balances in the unaudited condensed consolidated financial statements for the three and nine months ended January 31, 2025 have been reclassified to conform to the presentation in the condensed consolidated financial statements for the three and nine months ended January 31, 2026. In the prior year, the Company separately disclosed compensation expense, director fees and legal and professional expenses and combined the QCLS change in fair value of the investment and warrant assets and in the current year the Company has reclassified these costs on the consolidated statements of operations with general and administrative expenses and the change in the fair value of the investment QCLS and the change in the fair value of the warrant assets are presented separately. These reclassifications had no effect on the Company’s previously reported results of operations, changes in convertible preferred stock and stockholders’ equity, or cash flows.
Cash and Cash Equivalents
Cash and cash equivalents include cash in banks
and short-term liquid investments purchased with maturities of three months or less. Additionally, the Company, as of January 31, 2026
and April 30, 2025 had $
Intangible Assets
The Company’s accounts for intangible assets at cost. The intangible asset has an indefinite life; therefore, is not amortizable. The Company performs annual impairment analysis for the intangible asset to ascertain the value at each year end and records a non-cash impairment expense should the value decrease below book value. The asset is deemed to be an In-Process Research and Development (“IPR&D”) as the asset is in the research stage.
The Financial Accounting Standards Board (“FASB”) standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its reporting year.
Fair Value of Financial Instruments
Accounting Standards Codification (“ASC”) Topic 820, “Fair Value Measurements and Disclosures,” requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, “Financial Instruments,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the Consolidated Balance Sheets for current assets and liabilities qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments and their expected realization and their current market rate of interest. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of valuation hierarchy are defined as follows:
| · | Level 1. Observable inputs such as quoted prices in active markets | |
| · | Level 2. Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly; and | |
| · | Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. |
These unobservable inputs are significant to the fair value measurement.
| 13 |
Segment Reporting
The Company operates in business segment, which includes the business of research and development activities related to developing cellular cancer therapies. The determination of a single business segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its President and CEO, who reviews and evaluates consolidated net income as presented in the accompanying consolidated statements of operations for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.
New Accounting Pronouncement Effective in Future Periods
In December 2025, the FASB issued ASU 2025-11 – Interim Reporting (Topic 270): Narrow-Scope Improvements to improve the guidance in Topic 270, Interim Reporting, by improving the navigability of the required interim disclosures and clarifying when that guidance is applicable. The amendments also provide additional guidance on what disclosures should be provided in interim reporting periods. The guidance is effective for the Company’s interim periods within annual reporting periods beginning after December 15, 2027. The Company is evaluating the impact of adoption of this standard on its financial statements and disclosures.
NOTE 4 – INVESTMENT IN DEBT AND EQUITY SECURITIES
INVESTMENT IN FEMASYS SECURITIES
On November 14, 2023, the Company entered into
a Securities Purchase Agreement (the “Femasys Purchase Agreement”) with Femasys Inc. (“Femasys”), pursuant to
which it agreed to purchase from Femasys for a sum of $
Pursuant to the terms of the Femasys Purchase Agreement, the Company’s Chief Executive Officer was appointed to the Femasys board of directors.
The convertible note receivable is not traded in active markets and the fair value was historically determined using a Monte Carlo simulation. The convertible note receivable is accounted for as available-for-sale debt securities based on “Level 3” inputs, which consist of unobservable inputs and reflect management’s estimates of assumptions that market participants would use in pricing the asset. The Company elected the fair value option for the Femasys Note, therefore, holding gains and losses are included within change in fair value of the note in the unaudited condensed consolidated statement of operations. The Femasys Warrants are accounted for as an equity security and are valued using a Monte Carlo simulation based on “Level 3” inputs, which consist of unobservable inputs and reflect management’s estimates of assumptions that market participants would use in pricing the asset, recorded at fair value with subsequent changes included within change in fair value of the warrants in the unaudited condensed consolidated statement of operations.
As of January 31, 2026, the Company received $
During the three months ended January 31, 2026
and 2025, the Company recognized interest income of $
As of January 31, 2026, the fair value of the
Femasys Series A Warrants was approximately $
| 14 |
The Company recognized the Femasys Note and Femasys
Warrants based on their respective fair values as of April 30, 2025 of $
Below is a summary of activity for the Femasys Note and Femasys Warrants as of January 31, 2026:
| Balance of Femasys Note as of April 30, 2025 | $ | |||
| Change in fair value | ||||
| Settlement of Femasys Note | ( | ) | ||
| Balance of Femasys Note as of January 31, 2026 | $ | |||
| Balance of Femasys Warrant Asset as of April 30, 2025 | $ | |||
| Change in fair value | ( | ) | ||
| Balance of Femasys Warrant Asset as of January 31, 2026 | $ |
MARKETABLE SECURITIES
On November 21, 2025 and 2024, the Company
received from the Femasys Notes payments in Femasys common stock for interest income in the amount of $
Cost and fair value of marketable equity securities at January 31, 2026 are as follows:
| Carrying Value | ||||||||||||
| At Fair Market | Adjusted | Unrealized | ||||||||||
| Marketable securities | Value | Cost Basis | Loss | |||||||||
| Equity – stock | $ | $ | $ | |||||||||
The fair value of equity securities has been measured on a recurring basis using Level 1 inputs, which are based on unadjusted quoted market prices within active markets. There have been no changes in valuation approaches or techniques and related inputs.
| 15 |
INVESTMENT IN Q/C TECHNOLOGIES, INC.
Series G Preferred Shares and Warrants
On May 20, 2024, the Company entered into a Securities
Purchase Agreement (the “Series G SPA”) with a public company operating in the medical industry, MyMD Pharmaceuticals, Inc.
which subsequently changed its name to TNF Pharmaceuticals, Inc. and then to Q/C Technologies, Inc., (“QCLS”). Pursuant to
the Series G SPA, the Company purchased (i) shares of QCLS’s Series G Convertible Preferred Stock (the “Series G Preferred
Shares” or “Series G Preferred Stock”) with an original conversion price of $1.816 per Series G Preferred Share, which
were initially convertible into 3,854,626 shares of common stock of QCLS (“QCLS Common Stock”); (ii) warrants to purchase
up to
In April 2025, QCLS issued securities that caused
changes to the original terms of the Series G Preferred Stock. The conversion and exercises prices were adjusted to $0.1832 per Series
G Preferred Share, the number of QCLS Series G Long-Term Warrants were adjusted to purchase
Pursuant to the Series G SPA, the Company has the right to participate in future sales of QCLS’s equity and equity-linked securities until the second anniversary of the Closing or the date on which no Series G Preferred Shares remain outstanding, whichever is earlier. Additionally, the Company has the right to nominate one individual to serve on QCLS’s board of directors until PharmaCyte no longer beneficially owns at least 20% of QCLS Common Stock on an as-converted basis. The Company’s Chief Executive Officer serves on the board of directors of QCLS.
The Company determined that QCLS is a VIE, since QCLS does not have sufficient equity at risk to finance its own operations without additional subordinated financial support. However, the Company has determined that it is not the primary beneficiary of QCLS. Furthermore, Series G Preferred Stock is not considered in substance common stock, and as such, the equity method of accounting does not apply. The Company recorded its investment in Series G Preferred Stock at its fair value as the Company did not elect the measurement alternative to account for the investment at cost less impairment. Subsequent changes in fair value of the Series G Preferred Stock are recognized in earnings at each reporting period. The fair value of the Series G Preferred Stock was estimated utilizing a Monte Carlo simulation.
The QCLS Series G Warrants were determined to meet the definition of a derivative and were required to be recorded at fair value in accordance with ASC 815. Subsequent changes in the fair value of the QCLS Series G Warrants are recognized in earnings, at each reporting date. The issuance date fair value of the QCLS Series G Warrants was determined utilizing the Black Scholes Merton Method.
The Series G Preferred Stock shares include a 10% dividend, which are payable in cash or shares of QCLS Series G Preferred Stock at the Company’s option, and the Company has elected to receive shares of the QCLS Preferred Stock as Payment in Kind (“PIK”). As of January 31, 2026, and April 30, 2025 the Company owned shares including accrued dividend of shares, and Series G Preferred Stock shares, respectively.
| 16 |
During the three and nine months ended January
31, 2026, the Company recognized a gain for the change in fair value of the Series G Preferred Stock of $
During the three and nine months ended January
31, 2026, the Company recognized a loss of $
Below is a summary of activity for the Series G Preferred Stock as of January 31, 2026:
| Balance of Series G Preferred Stock as of April 30, 2025 | $ | |||
| Change in fair value | ( | ) | ||
| Balance of Series G Preferred Stock as of January 31, 2026 | $ | |||
Below is a summary of activity for the QCLS Warrants as of January 31, 2026:
| Balance of QCLS Series G Warrant assets as of April 30, 2025 | $ | |||
| Change in fair value | ( | ) | ||
| Balance of QCLS Series G Warrant assets as of January 31, 2026 | $ | |||
Series H Preferred Shares and Warrants
On September 2, 2025, the Company entered into
a Securities Purchase Agreement (the “Series H SPA”) with QCLS. Pursuant to the Series H SPA, the Company purchased (i)
shares of QCLS’s Series H Convertible Preferred Stock (the “Series H Preferred Shares” or “Series H Preferred
Stock”), at a stated value of $1,000 per Series G Preferred Share, with an initial conversion price of $5.00 which were initially
convertible into 600,000 shares of QCLS Common Stock ; (ii) warrants to purchase up to
In September 2025, in connection with the QCLS’
1-for-100 reverse stock split and pursuant to the stock combination event adjustment provisions of the Series H Preferred Shares and QCLS
Series H Warrants, the conversion price and the exercise price was adjusted to $
The Series H Preferred Stock is not considered
in substance common stock, and as such, the equity method of accounting does not apply. The Company recorded its investment in Series
H Preferred Stock at its fair value as the Company did not elect the measurement alternative to account for the investment at cost less
impairment. Subsequent changes in fair value of the Series H Preferred Stock are recognized in earnings at each reporting period. The
initial fair value of the Series H Preferred Stock of $
| 17 |
The QCLS Series H Warrants were determined to
meet the definition of a derivative and were required to be recorded at fair value in accordance with ASC 815. Subsequent changes in the
fair value of the QCLS Series H Warrants are recognized in earnings, at each reporting date. The issuance date fair value of the QCLS
Series H Warrants of $
The total aggregated fair value of the QCLS Series
H Preferred Stock and the QCLS Series H Warrants of $
During the three and nine months ended January
31, 2026, the Company recognized a gain on the change in fair value of the Series H Preferred Stock of $
During the three and nine months ended January
31, 2026, the Company recognized a gain of $
The Company has determined that QCLS is a VIE, as QCLS does not have sufficient equity at risk to finance its own operations without additional subordinated financial support. However, the Company has determined that it is not the primary beneficiary of QCLS.
Below is a summary of activity for the Series H Preferred Stock as of January 31, 2026:
| Balance of Series H Preferred Stock as of April 30, 2025 | $ | |||
| Initial fair value of investment Series H Preferred Shares | ||||
| Change in fair value | ||||
| Balance of Series H Preferred Stock as of January 31, 2026 | $ | |||
Below is a summary of activity for the QCLS Series H Warrants as of January 31, 2026:
| Balance of QCLS Series H Warrant assets as of April 30, 2025 | $ | |||
| Initial fair value of investment in of QCLS Series H Warrants | ||||
| Change in fair value | ||||
| Balance of QCLS Series H Warrant assets as of January 31, 2026 | $ | |||
| 18 |
NOTE 5 – ACCRUED EXPENSES
Accrued expenses at January 31, 2026 and April 30, 2025, are summarized below:
| January 31, 2026 | April 30, 2025 | |||||||
| Payroll related costs | $ | $ | ||||||
| Director fees | ||||||||
| R&D costs | ||||||||
| Legal settlement | ||||||||
| Excise tax on stock repurchases | ||||||||
| Total accrued expenses | ||||||||
| Less: Long-term portion of legal settlement | ( | ) | ||||||
| Total | $ | $ | ||||||
2021 Equity Incentive Plan
Effective June 30, 2021, the Company implemented the 2021 Equity Incentive Plan (“2021 Equity Plan”) as approved by the Company’s stockholders. The 2021 Equity Plan is administered by the Compensation Committee of the Board and has shares authorized under this plan. The 2021 Equity Plan can issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2021 Equity Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive stock options (“ISOs”) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted to any 10% shareholder). As of January 31, 2026, there are shares remaining available under the 2021 Equity Plan.
2022 Equity Incentive Plan
Effective December 28, 2022, the Company implemented the 2022 Equity Incentive Plan (“2022 Equity Plan”) as approved by the Company’s stockholders. In October 2025, the Company held a special meeting of stockholders (the “2025 Special Meeting”). At the 2025 Special Meeting, the stockholders of the Company approved an amendment to the 2022 Equity Plan which, among other things, increased the number of shares of common stock available for grant under the 2022 Equity Plan by . The 2022 Equity Plan is administered by the Compensation Committee of the Board and has shares available under this plan, as amended. The 2022 Equity Plan can issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2022 Equity Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive stock options (“ISOs”) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted to any 10% shareholder). As of January 31, 2026, there are shares remaining available under the 2022 Equity Plan.
| 19 |
Stock Options
A summary of the Company’s stock option activity and related information for the nine months ended January 31, 2026, are shown below:
| Options | Number of Options | Weighted Average Exercise Price per Share | Weighted Average Remaining Contractual Term in Years | |||||||||
| Outstanding, April 30, 2025 | $ | |||||||||||
| Issued | – | |||||||||||
| Expired and forfeited | ( | ) | – | |||||||||
| Outstanding, January 31, 2026 | $ | |||||||||||
| Exercisable, January 31, 2026 | $ | |||||||||||
The Company recorded $ and $ of stock-based compensation expense related to the issuance of Employee Options to certain officers and directors in exchange for services during the three and nine months ended January 31, 2026, respectively, and $ and $ for the three and nine months ended January 31, 2025, respectively. As of January 31, 2026, there remained $ of unrecognized compensation expense related to unvested Employee Options granted to officers and directors.
The aggregate intrinsic value of vested outstanding options as of January 31, 2026 was $.
Warrants
Series B Warrant
On May 10, 2023, the Company entered into a Securities
Purchase Agreement (the “Private Placement Agreement”) with certain accredited investors (the “Investors”), pursuant
to which it agreed to sell to the Investors warrants to acquire up to an aggregate of
The Series B Warrants were determined to be subject to liability classification as they are considered to be indexed to the Company’s own stock but fail to meet the requirements for equity classification in accordance with ASC 815. As such, the Company recorded the Series B Warrants as a liability at fair value with subsequent changes in fair value recognized in earnings. The Company utilized the Black-Scholes-Merton Model to calculate the value of the Series B Warrants issued on May 10, 2023.
During the three and nine months ended January
31, 2026, the Company received Series B exercise notices totaling shares. The exercises resulted in the Company received cash
in the amount of $
| 20 |
During the three and nine months ended January
31, 2026, the Company recorded a gain of approximately $
During the three and nine months ended January
31, 2025, the Company recorded a gain of approximately $
Settlement Warrants
In connection with the Settlement Agreement, as
defined on Note 8 – Commitments and Contingencies, on May 16, 2025, the Company issued warrants (“First Warrant Issuance”)
to purchase
The Settlement Warrants were determined to be subject to liability classification. As such, the Company recorded the Settlement Warrants as a liability upon issuance at their fair value with subsequent changes in fair value recognized in earnings.
The Company utilized the Black-Scholes-Merton Model to calculate the value of the Settlement Warrants issued during the three and nine months ended January 31, 2026.
The fair value of the First Warrant Issuance of
approximately $
The fair value of the Additional Warrants of approximately
$
During the three and nine months ended January
31, 2026, the Company recorded a gain on legal settlement of $
During the three and nine months ended January
31, 2026, the Company recorded a gain of $
| 21 |
Series C Warrant
On August 17, 2025, the Company entered into a
Securities Purchase Agreement (the “Series C Private Placement Agreement”) with certain accredited investors (the “Investors”),
pursuant to which it agreed to sell in a private placement to the Investors warrants to acquire up to an aggregate of
The Series C Warrants were determined to be subject
to liability classification as they are considered to be indexed to the Company’s own stock but fail to meet the requirements for
equity classification in accordance with ASC 815. As such, the Company recorded the Series C Warrants as a liability at fair value with
subsequent changes in fair value recognized in earnings. The fair value of the Series C Warrants of $
During the three and nine months ended January
31, 2026, the Company recorded a gain of approximately $
Placement Agent Warrants
In connection with the Series C Private Placement
Agreement, the Company also issued warrants to purchase up to an aggregate of
The Series C Placement Agent Warrants are classified as a contingently redeemable warrant in accordance with ASC 718, as it was determined that the warrants were not precluded from equity classification under that guidance, but could be settled in cash or other assets in the event that another person or entity becomes the beneficial owner of 50% of the outstanding shares of the Common Stock. The Series C Placement Agent Warrants were thus classified in temporary equity on the Company’s condensed consolidated balance sheets as of January 31, 2026 pursuant to ASC 480-10-S99-3A.
The fair value of the Series C Placement Agent
Warrants of $
A summary of the Company’s warrant activity and related information for the nine months ended January 31, 2026, are shown below:
| Warrants | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Term In Years | ||||||||||
| Outstanding, April 30, 2025 | $ | |||||||||||
| Issued | – | |||||||||||
| Issued - Series B Warrants and Settlement Warrants adjusted | – | |||||||||||
| Exercised | ( | ) | – | |||||||||
| Expired | – | |||||||||||
| Outstanding, January 31, 2026 | ||||||||||||
| Exercisable, January 31, 2026 | $ | |||||||||||
| 22 |
NOTE 7 – OTHER RELATED PARTY TRANSACTIONS
The Company had the following related party transactions during the three and nine months ended January 31, 2026 and 2025, respectively.
The Company owns
In April 2014, the Company entered into the
Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona
is owned by Prof. Günzburg and Dr. Salmons, both of whom are involved in numerous aspects of the Company’s scientific
endeavors relating to cancer (Prof. Günzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and
President of Austrianova). The term of the agreement is for 12 months and is automatically renewable for successive 12-month terms.
After the initial term, either party can terminate the agreement by giving the other party 30 days’ written notice before the
effective date of termination. To date, the agreement has been automatically renewed annually. The amounts incurred for the three
and nine months ended January 31, 2026 were approximately $
The Company’s Chief Executive Officer was appointed to the Femasys board of directors, see Note 4 – Investment in Debt and Equity Securities.
The Company’s Chief Executive Officer serves on the board of directors as the executive chairman of QCLS, see Note 4 – Investment in Debt and Equity Securities.
NOTE 8 – COMMITMENTS AND CONTINGENCIES
The Company acquires assets still in development
and enters R&D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon
the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent
upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the
product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based
upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained. For the three and nine
months ended January 31, 2026 the Company expensed $
There are future royalty payments as follows:
| · | Four percent royalty on all gross sales received by us or the Company’s affiliates; | |
| · | Twenty percent royalty on gross revenues received by the Company or the Company’s affiliates from a sublicense or right to use the patents or the licenses granted by the Company or the Company’s affiliates; | |
| · | Fifty percent of any other financial and non-financial consideration received from sublicensees of the Cell-in-a-Box® technology; and | |
| · | The removal of all milestone payments. |
| 23 |
Office Lease
In January 2023, the Company entered into a month-to-month agreement of the Las Vegas office space, commencing on May 1, 2023. Additionally, the Company rents storage space pursuant to a month-to-month agreement in Laguna Hills, California.
Rent expenses for these offices for the three
and nine months ended January 31, 2026 were $
With the month-to-month office rental agreements there are no aggregate future minimum lease payments required to be made.
Service Agreements
The Company has entered into several service agreements
with independent and related parties pursuant to which services will be provided over a specified period-of-time related to the IND which
the FDA has placed on clinical hold. The services include regulatory affairs strategy, advice and follow-up work on the IND and services
related to having the clinical hold lifted. The total remaining cost is estimated to be approximately $
Legal Proceedings
From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company’s financial condition or operating results.
On May 16, 2025, the Company entered into a settlement
and release agreement (“Settlement Agreement”) with H.C. Wainwright & Co., LLC relating to a complaint filed on December
4, 2023, alleging a breach of contract. The Settlement Agreement resolved fully all differences, disputes or claims without admitting
any liability, fault or wrongdoing on the part of all parties. The Settlement Agreement required the Company to pay $
On August 19, 2025, pursuant to the warrant terms,
the exercise price of the First Warrant Issuance and the Additional Warrants was adjusted to $
To the Company’s knowledge there are no other legal proceedings pending to which any property of the Company is subject.
| 24 |
The Company computes basic earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation formula that determines earnings per share for common stock and any participating securities according to dividends declared (whether paid or unpaid) and participation rights in undistributed earnings. The Series B Preferred Shares and Series C Preferred Shares are considered participating securities as preferred shareholders are entitled to participate with common stockholders on an as-converted basis in any distributions of assets by the Company under the terms of their respective Certificates of Designations. Diluted earnings per share for the nine months ended January 31, 2025 was computed using the two-class method. Under the two-class method, there is no change in the weighted average shares outstanding used between the basic and diluted earnings per share calculations as the Series B Preferred Shares represent the only dilutive share equivalents during the nine months ended January 31, 2025.
During the three and nine months ended January 31, 2026 and the three months ended January 31, 2025 the Company incurred losses attributable to common shareholders. Accordingly, the effects of any common stock equivalent would be anti-dilutive during the period and thus are not included in the calculation of diluted weighted average number of shares outstanding.
The following table illustrates the computation of basic and diluted earnings (loss) per share:
| Three Months Ended January 31, | ||||||||
| 2026 | 2025 | |||||||
| Earnings per share | ||||||||
| Net loss | $ | $ | ( | ) | ||||
| Less: Accretion of discounts to redemption of convertible preferred stock | ( | ) | ||||||
| Less: Convertible preferred stock dividends | ( | ) | ||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | ||
| Weighted average shares outstanding used in basic and diluted earnings per share | ||||||||
| Net loss per share basic and diluted | $ | ) | $ | ) | ||||
| Nine Months Ended January 31, | ||||||||
| 2026 | 2025 | |||||||
| Earnings per share | ||||||||
| Net income (loss) | $ | ( | ) | $ | ||||
| Less: Accretion of discounts to redemption of convertible preferred stock | ( | ) | ( | ) | ||||
| Less: Convertible preferred stock dividends | ( | ) | ( | ) | ||||
| Less: Allocation of undistributed income to Series B convertible preferred stock | ( | ) | ||||||
| Undistributed income (loss) available to common stockholders | $ | ( | ) | $ | ||||
| Weighted average shares outstanding used in basic earnings per share | ||||||||
| Net income (loss) per share basic and diluted | $ | ) | $ | |||||
| 25 |
The table below sets forth the potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive:
| Three and Nine Months Ended January 31, | ||||||||
| 2026 | 2025 | |||||||
| Excluded options | ||||||||
| Excluded preferred shares | ||||||||
| Excluded warrants | ||||||||
| Total excluded options, preferred shares and warrants | ||||||||
Diluted earnings per share were calculated under both the if-converted and the two-class methods to determine the most dilutive amount for the common stock. The Company applied the treasury stock two-class method which assumes the securities remain in their current non-exercised or converted form and therefore, deemed anti-dilutive.
NOTE 10 – PREFERRED STOCK
Series C Private Placement
On August 17, 2025, the Company entered into the
Series C Private Placement Agreement with the Investors, pursuant to which it agreed to sell to the Investors in a private placement (the
“Series C Private Placement”) (i) an aggregate of shares of the Company’s newly designated Series C convertible
preferred stock, par value $, with a stated value of $ per share (the “Series C Preferred Stock”), initially convertible
into up to shares of the Company’s common stock, par value $ per share at an initial conversion price of $
In connection with the Series C Private Placement,
pursuant to an Engagement Letter (the “Engagement Letter”) between the Company and the Placement Agent, the Company has agreed
to pay the Placement Agent
Transaction costs totaling $
| 26 |
Series C Preferred Stock
The terms of the Series C Preferred Stock are
as set forth in the form of Certificate of Designations (the “Certificate of Designations”). The Series C Preferred Stock
are convertible into shares of Common Stock (the “Conversion Shares”) at the election of the holder at any time at an initial
conversion price of $
The holders of the Series C Preferred Stock will be entitled to dividends of 7% per annum, compounded quarterly, which will be payable in cash. Upon the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designations), the Series C Preferred Stock will accrue dividends at the rate of 15% per annum. The holders of Series C Preferred Stock are entitled to vote with holders of the Common Stock as a single class on all matters that holders of Common Stock are entitled to vote upon, with the number of votes per Series C Preferred Share equal to the stated value of such Series C Preferred Share divided by the then applicable Conversion Price; provided, however that in no event shall the then applicable Conversion Price be less than the “Minimum Price” (as defined in Nasdaq Listing Rule 5635) on the date immediately prior to the date of the Purchase Agreement.
In October 2025, the Company held a special meeting of stockholders (the “2025 Special Meeting”). At the 2025 Special Meeting, the stockholders of the Company approved, for purposes of complying with Nasdaq Listing Rule 5635(d), (the “Exchange Cap”) the issuance of shares of Common Stock underlying the Series C Preferred Stock and Series C Warrants, which allows the Company to settle all Series C Preferred Stock conversions into shares of Common Stock. The Series C Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the issuance of shares of Common Stock issuable upon conversion of the Series C Preferred Stock or Series C Warrants.
The Company obtained stockholder approval to remove the Exchange Cap on October 30, 2025, upon which event the conversion floor price was adjusted to $0.19.
The Series C Certificate of Designations includes certain Triggering Events (as defined in the Series C Certificate of Designations), including, among other things, the Company’s failure to pay any amounts due to the holders of the Series C Preferred Stock when due. In connection with a Triggering Event, each holder of Series C Preferred Stock will be able to require the Company to redeem in cash any or all of the holder’s Series C Preferred Stock at a premium set forth in the Series C Certificate of Designations.
The Series C Preferred Shares were determined
to be more akin to a debt-like host than an equity-like host. The Company identified certain embedded features that were deemed not to
be clearly and closely related to the debt host instrument and were therefore bifurcated as a derivative under ASC 815. These features
were bundled together, assigned probabilities of being affected and measured at fair value. Subsequent changes in fair value of these
features are recognized in the condensed consolidated statement of operations. The Company estimated the $
The discount to the fair value is included as
a reduction to the carrying value of the Series C Preferred Stock. During the nine months ended January 31, 2026, the Company recorded
a total discount of $
| 27 |
During the three and nine months ended January
31, 2026, the Company recorded a gain of $
During the three and nine months ended January
31, 2026, the Company recognized a total of $
NOTE 11 – TREASURY STOCK
In May 2022, the Board authorized a share repurchase program to acquire its outstanding common stock for up to $10 million. In January 2023, the Board authorized an additional share repurchase program to acquire up to an additional $10 million of the Company’s outstanding common stock. In conjunction with the share repurchase programs, the Company selected a broker to repurchase shares on behalf of the Company. The amount of common stock repurchased on any given trading day is determined by a formula, which is based on the market price of the common stock and average daily volumes. Shares repurchased are held in treasury for general corporate purposes. The shares are treated as Treasury Stock using the cost method. As of April 2025, the Company has paused the repurchase program.
On December 11, 2025, the Company granted the
directors of the Company shares of common stock in a restricted stock unit (“RSU”) transaction. The RSUs vested immediately
and the Company withheld shares valued at $
As of January 31, 2026 and April 30, 2025, the
total number of shares held in Treasury Stock was and , respectively, shares at total costs of $
NOTE 12 – FAIR VALUE MEASUREMENTS
Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three and nine months ended January 31, 2026. The carrying amounts of cash equivalents, other current assets, accounts payable and accrued expenses approximate their face values at January 31, 2026 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible preferred stock was estimated using a probability-weighted scenario model, which uses as inputs the fair value of the Company’s common stock and estimates for the equity volatility and of the Company’s common stock, the time to maturity of the convertible preferred stock, the risk-free interest rate for a period of time that approximates the time to maturity, the maturity redemption premium rate, the liquidation premium rate, the market discount rate, and the dividend rate. The fair value of the warrant liability was estimated using the Black Scholes Merton Model which uses as inputs the following weighted average assumptions, as noted above: dividend yield, expected terms in years, equity volatility and risk-free rate.
| 28 |
Fair Value on a Recurring Basis
The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liability and bifurcated embedded derivative represent Level 3 measurements. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at January 31, 2026 and April 30, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
| Description | Level | January 31, 2026 | April 30, 2025 | |||||||||
| Liabilities: | ||||||||||||
| Warrant liabilities | 3 | $ | $ | |||||||||
| Derivative liabilities | 3 | $ | $ | |||||||||
The following table sets forth a summary of the change in the fair value of the warrant liability that is measured at fair value on a recurring basis:
| Three Months Ended January 31, 2026 | ||||
| Balance on October 31, 2025 | $ | |||
| Issuance of warrants | ||||
| Warrant exercises | ( | ) | ||
| Change in fair value of warrant liability | ( | ) | ||
| Balance on January 31, 2026 | $ | |||
| Nine Months Ended January 31, 2026 | ||||
| Balance on April 30, 2025 | $ | |||
| Issuance of warrants | ||||
| Warrant exercises | ( | ) | ||
| Change in fair value of warrant liability | ||||
| Balance on January 31, 2026 | $ |
The following table sets forth a summary of the change in the fair value of the derivative liability that is measured at fair value on a recurring basis:
| Three Months Ended January 31, 2026 | ||||
| Balance on October 31, 2025 | $ | |||
| Issuance of Series C convertible preferred stock | ||||
| Change in fair value of derivative liability | ( |
) | ||
| Balance on January 31, 2026 | $ | |||
| Nine Months Ended January 31, 2026 | ||||
| Balance on April 30, 2025 | $ | |||
| Issuance of Series C convertible preferred stock | ||||
| Change in fair value of derivative liability | ( |
) | ||
| Balance on January 31, 2026 | $ | |||
| 29 |
The fair value of the convertible note receivable was historically estimated using the income approach, which uses as inputs the fair value of debtor’s common stock and estimates for the equity volatility and volume volatility of debtor’s common stock, the time to expiration of the convertible note, the discount rate, the stated interest rate compared to the current market rate, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the estimate of expected future volatility is based on the actual volatility of debtor’s common stock and historical volatility of debtor’s common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using the S&P Global default rate for companies with a similar credit rating to debtor’s. At January 31, 2026, the fair value of the convertible note receivable was estimated to be equal to its principal value the note was near its maturity and was expected to be fully settled in cash.
The fair values of financial instruments by class as of January 31, 2026 and April 30, 2025 are as follows:
| Level | January 31, 2026 | April 30, 2025 | ||||||||||
| Financial Assets | ||||||||||||
| Marketable equity securities | 1 | $ | $ | |||||||||
| Money market account | 1 | $ | $ | |||||||||
| Convertible note receivable – investment in debt security - Femasys | 3 | $ | $ | |||||||||
| Warrant asset - Femasys | 3 | $ | $ | |||||||||
| Investment in preferred stock - QCLS | 3 | $ | $ | |||||||||
| Warrant assets - QCLS | 3 | $ | $ | |||||||||
Assumptions used in the valuation of the Level 3 assets include time to expiration, discount rate, risk-free rate, volatility and probability of default.
| 30 |
Item 2. Management’s Discussion and Analysis of Financial Conditions and Results of Operations.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (“Report”) includes “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements other than statements of historical fact are “forward-looking statements” for purposes of this Report, including any projections of earnings, revenue or other financial items, any statements regarding the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, any statements regarding expected benefits from any transactions and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by use of terminology such as “may,” “will,” “should,” “believes,” “intends,” “expects,” “plans,” “anticipates,” “estimates,” “goal,” “aim,” “potential” or “continue,” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained in this Report are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. Thus, investors should refer to and carefully review information in future documents we file with the U.S. Securities and Exchange Commission (“Commission”). Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risk and uncertainties, including, those set forth in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report, those set forth from time to time in our other filings with the Commission, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2025 and the following factors and risks:
Among others, these include:
| · | our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; | |
| · | whether the United States (“U.S.”) Food and Drug Administration (“FDA”) approves our Investigational New Drug Application (“IND”) after we complete the FDA’s requested studies and submit a response to the FDA’s clinical hold, so that we can commence our planned clinical trial involving locally advanced, inoperable, non-metastatic pancreatic cancer (“LAPC”); | |
| · | the success and timing of our preclinical studies and clinical trials; | |
| · | the potential that results of preclinical studies and clinical trials may indicate that any of our technologies and product candidates are unsafe or ineffective; | |
| · | our dependence on third parties in the conduct of our preclinical studies and clinical trials; | |
| · | the difficulties and expenses associated with obtaining and maintaining regulatory approval of our product candidates; | |
| · | the material adverse impact that the coronavirus pandemic may have on our business, including our planned clinical trial involving LAPC, which could materially affect our operations as well as the business or operations of third parties with whom we conduct business; | |
| · | whether the FDA will approve our product candidates after our clinical trials are completed, assuming the FDA allows our clinical trials; | |
| · | our ability to comply with the listing requirements of The Nasdaq Capital Market and any delisting or potential delisting of shares of our common stock; and | |
| · | other risks and uncertainties, including those listed in “Risk Factors.” |
| 31 |
All forward- looking statements and reasons why results may differ included in this Report are made as of the date hereof, and we do not intend to update any forward-looking statements except as required by law or applicable regulations. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements.
Except where the context otherwise requires, in this Report, the “Company,” “we,” “us” and “our” refer to PharmaCyte Biotech, Inc., a Nevada corporation, and, where appropriate, its subsidiaries.
Overview of Business
We are a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC, will be developed. The current generation of our product candidate is referred to as “CypCaps™.”
During the year ended April 30, 2024, we determined that research and development in the treatment of diabetes would no longer be pursued.
On August 15, 2022, we entered into a Cooperation Agreement (the “Cooperation Agreement”) with Iroquois Master Fund Ltd. and its affiliates, pursuant to which we elected a reconstituted board of directors (the “Board”). On November 17, 2023, the Board formed the Strategic Scientific Committee (the “Scientific Committee”), chaired by Dr. Michael Abecassis. The Scientific Committee and our independent consultants are reviewing many of the risks relative to our business. In addition, the Board is reviewing risks associated with our development programs and our relationship with SG Austria Pte. Ltd (“SG Austria”), including that all licensed patents have expired and that know-how relating to our Cell-in-a-Box® technology solely resides with SG Austria. The Board has reduced spending on our programs, including pre-clinical and clinical activities, until the review by the Scientific Committee and the Board is complete and the Board has determined the actions and plans to be implemented. The Scientific Committee’s recommendations will include potentially seeking a new framework for our relationship with SG Austria and its subsidiaries. We are reevaluating those programs which are dependent on SG Austria and the U.S. Food and Drug Administration’s (the “FDA”) acceptance of its technologies, including our development programs for locally advanced, inoperable, non-metastatic pancreatic cancer (“LAPC”). Our reevaluation for addressing the FDA concerns has resulted in delays stemming from the review of the non-clinical package provided by SG Austria and changes to the FDA review process.
The Cell-in-a-Box® encapsulation technology is designed to present genetically engineered live human cells to targeted tissues. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated, grown to confluence and maintained in a cryopreserved (frozen) state until shortly before they are injected into an appropriate patient. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish. Encapsulated cells are protected from environmental challenges, such as the shear forces associated with bioreactors and passage through catheters and needles, which we believe enables greater cell growth and production of the active molecules. The capsules are largely composed of cellulose (cotton) and are bioinert. During the past year, SG Austria has generated data and reports to support submission to the FDA concerning the safety of the microcapsules.
We have been developing therapies for pancreatic tumors by using genetically engineered live human cells that we believe are capable of converting a cancer prodrug into its cancer-killing form. We encapsulate those cells using the Cell-in-a-Box® technology and place those capsules in the body as close as possible to the tumor. In this way, we believe that when a cancer prodrug is administered to a patient with a particular type of cancer that may be affected by the resulting active drug, the killing of the patient’s cancerous tumor may be optimized both by enhanced potency and limited exposure away from the target tumor. We believe that the prodrug/activator technology is well suited to address the shift from cure/enhanced survival to creating a zone of clearance around blood vessels adjacent to tumor. This zone of clearance improves the probability of successful surgical resection of LAPC, which has been shown to improve survival.
| 32 |
In addition to reengaging SG Austria, we are also identifying alternative approaches to expand the prodrug/activator technology for cancer treatment. These discussions may expand our prodrug/activation options to use highly toxic cancer-killing drugs in tightly controlled perivascular spaces.
Until the Strategic Scientific Committee completes its evaluation of our programs and we enter into a new framework for its relationship with SG Austria, spending on our development programs has been curtailed.
Investigational New Drug Application and Clinical Hold
On September 1, 2020, we submitted an IND to the FDA for a planned clinical trial in LAPC. On October 1, 2020, we received notice from the FDA that it had placed our IND on clinical hold. On October 30, 2020, the FDA sent us a letter setting forth the reasons for the clinical hold and providing specific guidance on what we must do to have the clinical hold lifted.
In order to address the clinical hold, the FDA has requested that we:
| · | Provide additional sequencing data and genetic stability studies; | |
| · | Conduct a stability study on our final formulated product candidate as well as the cells from our Master Cell Bank (“MCB”); | |
| · | Evaluate the compatibility of the delivery devices (the prefilled syringe and the microcatheter used to implant the CypCaps™) with our product candidate for pancreatic cancer; | |
| · | Provide additional detailed description of the manufacturing process of our product candidate for pancreatic cancer; | |
| · | Provide additional product release specifications for our encapsulated cells; | |
| · | Demonstrate comparability between the 1st and 2nd generation of our product candidate for pancreatic cancer and ensure adequate and consistent product performance and safety between the two generations; | |
| · | Conduct a biocompatibility assessment using the capsules material; | |
| · | Address specified insufficiencies in the Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File; | |
| · | Conduct an additional nonclinical study in animals to assess the safety, activity, and distribution of the product candidate for pancreatic cancer; and | |
| · | Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold and remove any statements not supported by the data we generated. |
| 33 |
The FDA also requested that we address the following issues as an amendment to our IND:
| · | Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency; | |
| · | Perform qualification studies for the drug substance filling step to ensure that the product candidate for pancreatic cancer remains sterile and stable during the filling process; | |
| · | Submit an updated batch analysis for the product candidate for the specific lot that will be used for manufacturing all future product candidates; | |
| · | Provide additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays; | |
| · | Provide a few examples of common microcatheters that fit the specifications in our Angiography Procedure Manual; | |
| · | Clarify the language in our Pharmacy Manual regarding proper use of the syringe fill with the product candidate for pancreatic cancer; and | |
| · | Provide a discussion with data for trial of the potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in our study population. |
The following provides a detailed summary of our activities to have the clinical hold lifted:
| · | Stability Studies on Our Clinical Trial Product Candidate for Pancreatic Cancer. We have successfully completed the required product stability studies. The timepoints were 3, 6, 9, 12, 18 and 24 months of our product candidate for pancreatic cancer being stored frozen at -80C. These studies included container closure integrity testing for certain timepoints. | |
| · | Additional Studies Requested by the FDA. We have successfully completed various additional studies requested by the FDA, including a stability study on the cells from our MCB used to make our CypCaps™. | |
| · | Determination of the Exact Sequence of the Cytochrome P450 2B1 Gene. We have completed the determination of the exact sequence of the cytochrome P450 2B1 gene inserted at the site previously identified on chromosome 9 using state-of-the-art nanopore sequencing. This is a cutting edge, unique and scalable technology that permits real-time analysis of long DNA fragments. The result of this analysis of the sequence data confirmed that the genes are intact. | |
| · | Confirmation of the Exact Sequence of the Cytochrome P450 2B1 Gene Insert. An additional, more detailed analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that is used in our CypCaps™ was found to be intact. In this new study, we were able to confirm the previously determined structure of the integrated transgene sequence using more data points. These studies also set the stage for a next step analysis to determine the genetic stability of the cytochrome P450 2B1 gene at the DNA level after multiple rounds of cell growth. This new study has been completed in which our original Research Cell Bank (“RCB”) cells were compared with cells from the MCB. The analysis confirmed that the cytochrome P450 2B1 and the surrounding sequence has remained stable with no changes detected at the DNA level. | |
| · | Biocompatibility Studies. We have been involved with 10 biocompatibility studies requested by the FDA, eight of which have been completed successfully. To enable the biocompatibility studies to be performed, we had Austrianova Singapore Pte. Ltd. (“Austrianova”) manufacture an additional 400 syringes of empty capsules. |
| 34 |
| · | Systemic Toxicity Testing. We evaluated the potential toxicity of the capsule component of our product candidate for pancreatic cancer and determined there is no evidence of toxicity in any of the parameters examined. The study also confirmed previous data that shows our capsule material is bioinert. | |
| · | Micro-Compression and Swelling Testing. This testing is underway. We are developing and optimizing two reproducible methods for testing and confirming the physical stability and integrity of our CypCaps™ under extreme pressure. These studies required the acquisition of new equipment by Austrianova as well as validation and integration into Austrianova’s Quality Control laboratory. | |
| · | Break Force and Glide Testing. We are in the process of developing a protocol to measure whether the syringe, attached to the catheter when used to expel the capsules, will still have a break and glide force that is within the specifications we have established. We are setting the specifications based on the syringe/plunger manufacturer’s measured break and glide forces, or alternatively, accepted ranges for glide forces routinely used in the clinic. | |
| · | Capsules Compatibility with the Syringe and Other Components of the Microcatheter Delivery System. We are in the process of showing that CypCaps™ are not in any way adversely affected by the catheters used by interventional radiologists to deliver them into a patient. Compatibility data is being generated to demonstrate that the quality of the CypCaps™ is maintained after passage through the planned microcatheter systems. | |
| · | CypCaps Capsules and Cell Viability after Exposure to Contrast Medium. We have commenced testing to show that exposure of CypCaps™ to the contrast medium interventional radiologists used to implant the CypCaps™ in a patient has no adverse effect on CypCaps™. Contrast medium is used to visualize the blood vessels during implantation. | |
| · | Master Drug File Information. Austrianova is providing additional detailed confidential information on the manufacturing process, including information on the improvements and advancements made to our product candidate for pancreatic cancer since the last clinical trials were conducted with respect to reproducibility and safety. However, Austrianova has not changed the overall physical characteristics of CypCaps™ between the 1st and 2nd generations. | |
| · | Submission of Data to FDA. We are in the process of providing these data to the FDA. The clinical hold did not reflect any deficiencies of the clinical trial proposed. We seek to resolve these non-clinical issues to enable FDA review of a new clinical protocol that reflects the standard of care for LAPC. |
We assembled a scientific and regulatory team of experts to address the FDA requests. Through January 31, 2026, our scientific consultants have been in active dialog with the FDA. We have received communications from the FDA and responded, including the submission of the updated drug master file. The FDA accepted the updated drug master file and cleared many of the clinical hold items. . We believe that the technology upon which the LAPC treatment will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans. Our position is that the data available from these human clinical trials supersedes large animal study data, making the study unnecessry. The treatment may not be a treatment of pancreatic cancer, but a method of improving and possibly enabling complete surgical resection of the tumor. We are waiting for the FDA’s responses and hope the FDA will accept that the LAPC treatment now meets manufacturing standard requirements, which have significantly improved since the clinical hold was first placed. The FDA may require additional preclinical studies when the meeting takes place. We are in ongoing dialogue with SG Austria to prepare for the next steps, including the preparation of the syringes filled with the latest generation of CypCaps™ with the working cell bank material.
Performance Indicators
Non-financial performance indicators used by management to manage and assess how the business is progressing will include, but are not limited to, the ability to: (i) acquire appropriate funding for all aspects of our operations; (ii) acquire and complete necessary contracts; (iii) complete activities for producing genetically modified human cells and having them encapsulated for our preclinical studies and the planned clinical trial in LAPC; (iv) have regulatory work completed to enable studies and trials to be submitted to regulatory agencies; (v) complete all required tests and studies on the cells and capsules we plan to use in our clinical trial in patients with LAPC; (vi) ensure completion of the production of encapsulated cells according to cGMP regulations to use in our planned clinical trial; (vii) complete all of the tasked the FDA requires of us in order to have the clinical hold lifted; and (viii) obtain approval from the FDA to lift the clinical hold on our IND that we may commence our planned clinical trial in LAPC.
| 35 |
There are numerous items required to be completed successfully to ensure our final product candidate is ready for use in our planned clinical trial in LAPC. The effects of material transactions with related parties, and certain other parties to the extent necessary for such an undertaking, may have substantial effects on both the timeliness and success of our current and prospective financial position and operating results. Nonetheless, we are actively working to ensure strong ties and interactions to minimize the inherent risks regarding success. We do not believe there are factors which will cause materially different amounts to be reported than those presented in this Report. We aim to assess this regularly to provide accurate information to our shareholders.
Recent Developments
Nasdaq Minimum Bid Price Requirement
On December 1, 2025, we received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that we are not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market. The Bid Price Rule requires listed securities to maintain a minimum bid price of $1.00 per share, and, based on the closing bid price of our Common Stock for the 30 consecutive business days preceding the date of the Notice, we no longer satisfy this requirement.
The Notice has no immediate effect on the listing or trading of our Common Stock on The Nasdaq Capital Market, and our Common Stock will continue to trade under the symbol “PMCB.” The Notice does not affect our business operations or our reporting obligations with the Securities and Exchange Commission.
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided an initial period of 180 calendar days, or until June 1, 2026 (the “Compliance Date”), to regain compliance with the Bid Price Rule. If at any time during this 180-day period the closing bid price of our Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days (or for such longer period as the Nasdaq staff may determine is necessary under Nasdaq Listing Rule 5810(c)(3)(H)), Nasdaq will provide us with written confirmation of compliance, and the matter will be closed.
If we do not regain compliance by the Compliance Date, we may be eligible for an additional 180-day compliance period if we (i) meet all applicable continued listing requirements for initial listing on The Nasdaq Capital Market (other than the minimum bid price requirement) and (ii) provide Nasdaq with written notice of our intention to cure the deficiency during the second compliance period, which may include effecting a reverse stock split, if necessary. If we do not qualify for the second compliance period or fail to regain compliance during any additional compliance period granted, Nasdaq will provide written notification to us that our securities are subject to delisting. In such event, we would be entitled to appeal Nasdaq’s determination to a Nasdaq Hearings Panel.
We intend to actively monitor the closing bid price of our Common Stock and will consider all available options to regain compliance with the Bid Price Rule, including, if appropriate, implementing a reverse stock split, subject to stockholder approval. There can be no assurance that we will be able to regain or maintain compliance with the Bid Price Rule or the other continued listing requirements of The Nasdaq Capital Market.
Results of Operations
Three and nine months ended January 31, 2026, compared to three and nine months ended January 31, 2025
Revenue
We had no revenues for the three and nine months ended January 31, 2026, and 2025.
| 36 |
Research and development expenses
R&D expense was $93,113 for the three months ended January 31, 2026, as compared to $118,196 for the three months ended January 31, 2025, a decrease of $25,083. The change in cost is primarily due to nonrecurring expenditures in our use of consultants to conduct research into the treatment of pancreatic cancer.
R&D expense was $329,355 for the nine months ended January 31, 2026, as compared to $311,682 for the nine months ended January 31, 2025, an increase of $17,673. The change in cost is primarily due to our continued strategy utilizing consultants to conduct research into the treatment of pancreatic cancer.
General and administrative expenses
General and administrative expenses consist primarily of costs associated with our overall operations and with being a public company. These costs include personnel, legal and professional services, insurance, investor relations and compliance related fees. These expenses were $2,024,989 and $842,056, respectively, for the three months ended January 31, 2026 and 2025, an increase of $1,182,933, or 141%. Stock-based compensation expenses increased by $880,130 primarily due to a restricted stock unit (“RSU”) granted to our CEO and directors, and investor relations and filing fees increased by $48,741 due to stockholder meetings requiring more attempts to reach investors. Legal and professional fees increased by $246,096 primarily due to an increase in consulting fees relating to capital raise costs.
General and administrative expenses consist primarily of costs associated with our overall operations and with being a public company. These costs include personnel, legal and professional services, insurance, investor relations and compliance related fees. These expenses were $4,013,103 and $3,024,316, respectively, for the nine months ended January 31, 2026 and 2025, an increase of $988,787, or 33%. Stock-based compensation expenses increased by $659,283 primarily due to an increase in RSU to our CEO and directors, and investor relations and filing fees increased by $138,035 due to stockholder meetings in 2026 requiring more attempts to reach investors. Legal and professional fees increased by $198,256 primarily due to an increase in consulting fees relating to non-recurring transactions.
Other Income (Expenses), Net
Other income (expenses), net, for the three months ended January 31, 2026 was $2,864,962 as compared to other income (expense), net of $(2,085,076) for the three months ended January 31, 2025. Other income (expenses), net, for the three months ended January 31, 2026 is attributable to interest income of $230,668, net of changes in fair value of warrant liabilities of $1,895,865, a change in the fair value of derivative liability of $557,000, a change in fair value of the Femasys warrant asset of $(214,000), a change in fair value of the QCLS investment of $1,725,000, a change in fair value of the QCLS warrant assets of $(1,200,000), a change in the unrealized loss on marketable securities of $(128,939), and other expenses of $(632). Other income (expenses), net, for the three months ended January 31, 2025, is attributable to interest income of $255,692, changes in fair value of warrant liability of $4,487,000, a change in fair value of convertible note receivable of $(79,000), a change in fair value of the Femasys warrant asset of $(596,000), a change in fair value of the QCLS investment of $(6,225,000), a change in the unrealized gain marketable securities of $72,632 and a net of other expenses of $(400). The changes to the fair values are a result of the updated inputs in the various calculations of fair values.
Other income (expenses), net, for the nine months ended January 31, 2026 was $(10,688,753) as compared to other income (expense), net of $22,242,466 for the nine months ended January 31, 2025. Other income (expenses), net, for the nine months ended January 31, 2026 is attributable to interest income of $654,848, net of changes in fair value of warrant liabilities of $(8,335,135), a change in the fair value of derivative liability of $859,000, a gain on the legal settlement revaluation of $106,000, a change in fair value of convertible note receivable of $1,304,000, a change in fair value of the Femasys warrant asset of $(2,155,000), a change in fair value of the QCLS investment of $(3,485,000), a gain on related party investment of $2,089,000, issuance costs on convertible preferred stock and warrants of $(1,234,553), a change in fair value of the QCLS warrant assets of $18,000, a change in the unrealized loss on marketable securities of $(294,065), a loss on the issuance of convertible preferred stock of $(215,000) and other expenses of $(848). Other income (expenses), net, for the nine months ended January 31, 2025, is attributable to interest income of $1,185,686, changes in fair value of warrant liability of $8,400,000, derivative liability of $2,184,000, a change in fair value of convertible note receivable of $601,000, a change in fair value of the Femasys warrant asset of $(1,830,000), a change in fair value of the QCLS investment and warrant assets of $(9,765,734), a gain on related party investment of $21,395,734, a change in the unrealized gain marketable securities of $72,632 net of other expenses of $(852). The changes to the fair values are a result of the updated inputs in the various calculations of fair values.
| 37 |
Discussion of Operating, Investing and Financing Activities
The following table presents a summary of our sources and uses of cash for the nine months ended January 31, 2026, and 2025.
| Nine Months Ended January 31, 2026 | Nine Months Ended January 31, 2025 | |||||||
| Net cash used in operating activities: | $ | (3,760,352 | ) | $ | (1,937,925 | ) | ||
| Net cash used in investing activities: | $ | 2,000,000 | $ | (7,000,000 | ) | |||
| Net cash used in financing activities: | $ | 6,751,395 | $ | (24,857,608 | ) | |||
| Effect of currency rate exchange | $ | 2,329 | $ | (975 | ) | |||
| Net increase (decrease) in cash and cash equivalents | $ | 4,993,372 | $ | (33,796,508 | ) | |||
Operating Activities:
The cash and cash equivalents used in operating activities for the nine months ended January 31, 2026 of $3,760,352 is mainly a result of the payment of $1,450,000 relating to the legal settlement accrued at April 30, 2025 and our general and administrative expenses. The cash and cash equivalents used in operating activities for the nine months ended January 31, 2025 of $1,937,925 is mainly a result of our general and administrative expenses.
Investing Activities:
The cash and cash equivalents for the nine months ended January 31, 2026 provided by investing activities is attributable to the collection of the Femasys note receivable in full in the amount of $5,000,000 and our entry into a Securities Purchase Agreement (the “Series H SPA”) with QCLS (defined below). Pursuant to the Series H SPA, the Company purchased (i) 3,000 shares of QCLS’s Series H Convertible Preferred Stock (the “Series H Preferred Shares” or “Series H Preferred Stock”), at a stated value of $1,000 per Series H Preferred Share, with an initial conversion price of $5.00 which were initially convertible into 600,000 shares of Common Stock; and (ii) warrants to purchase up to 600,000 shares of QCLS Common Stock with a five-year term (“QCLS Series H Warrant”), for a total purchase price of $3,000,000.
The cash and cash equivalents for the nine months ended January 31, 2025, is attributable to our entry into a Securities Purchase Agreement (the “SPA”) with MyMD Pharmaceuticals, Inc. which subsequently changed its name to TNF Pharmaceuticals, Inc., and then to Q/C Technologies, Inc., (“QCLS”) in conjunction with a new focus on the development of energy-efficient computing infrastructure. Pursuant to the SPA, the Company purchased (i) 7,000 shares of QCLS’s Series G Convertible Preferred Stock (the “Series G Preferred Shares” or “Series G Preferred Stock”) with an original conversion price of $1.816 per Series G Preferred Share, which were initially convertible into 3,854,626 shares of Common Stock (as defined below); (ii) warrants to purchase up to 3,854,626 shares of QCLS Common Stock with a five-year term (“QCLS Series G Long-Term Warrant”); and (iii) warrants to purchase up to 3,854,626 shares of QCLS Common Stock with a 18-month term (“QCLS Series G Short-Term Warrant”) (collectively, the “QCLS Series G Warrants”), for an aggregate purchase price of $7,000,000.
| 38 |
Financing Activities:
The cash and cash equivalents provided by financing activities for the nine months ended January 31, 2026 is attributable to our entry into a Securities Purchase Agreement pursuant to which we sold investors in a private placement (the “Series C Private Placement”) (i) an aggregate of 7,000 shares of the Company’s newly designated Series C convertible preferred stock, par value $0.0001, with a stated value of $1,000 per share (the “Series C Preferred Stock”), initially convertible into up to 7,000,000 shares of the Company’s common stock, par value $0.0001 per share at an initial conversion price of $1.00 and (ii) the Series C Warrants to purchase up to an aggregate of 7,000,000 shares of Common Stock. Proceeds from the Series C Private Placement net of cash issuance costs totaled $6,268,866. Additionally, during the nine months ended January 31, 2026, we paid investors $162,606 in dividends on the Series C Preferred Stock and we paid our directors $401,625 in the form of RSUs granted to our directors for the estimated income tax effect of the grants.
The cash and cash equivalents used in financing activities for the nine months ended January 31, 2025 is mainly attributable to the repurchase of our Common Stock of approximately $2,370,733 and redemption of Series B Preferred Stock of approximately $22,486,875.
Liquidity and Capital Resources
As of January 31, 2026, we had approximately $20.2 million in cash and cash equivalents as compared to approximately $15.2 million at April 30, 2025. We expect that our current cash and cash equivalents of approximately $19 million as of the filing of this Quarterly Report on Form 10-Q, will be sufficient to support its projected operating requirements and financial commitments for at least the next twelve months from the date of this Quarterly Report.
In August 2025, we entered into a securities purchase agreement pursuant to which we agreed to sell to investors in a private placement an aggregate of 7,000 shares of our newly designated Series C convertible preferred stock with a stated value of $1,000 per share and warrants to purchase up to 7 million shares of our Common Stock, resulting in aggregate gross proceeds of $7 million.
In September 2025, we entered into a securities purchase agreement pursuant to which we agreed to purchase in a private placement QCLS Series H convertible preferred stock initially convertible into 600,000 shares, subject to adjustment, of QCLS Common Stock and warrants for an aggregate purchase price of $3 million.
We expect to need additional capital in order to complete a clinical trial for the treatment of pancreatic cancer. If any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to our current stockholders and debt financing, if available, may involve restrictive covenants. If we are able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its product candidates that we would otherwise seek to develop or commercialize on its own, on terms that are not favorable to us. Our ability to access capital is not assured and, if not achieved on a timely basis, will likely have a material adverse effect on our business, financial condition and results of operations.
We operate in an industry that is subject to rapid technological change, competition and government regulation. Our operations are subject to significant risk and uncertainties including financial operational, technological, regulatory, and other risks. Such factors, include but not limited to, results of clinical testing and trial activities, the ability to obtain regulatory approval, the supply of needed materials, the ability to obtain manufacturing and the ability to raise capital to achieve strategic objectives.
| 39 |
Service Agreements
We entered into several service agreements, with both independent and related parties, pursuant to which services will be provided over the next twelve months related to the clinical hold on our IND submission involving LAPC. The services include developing studies and strategies relating to clearing the clinical hold. The total cost is estimated to be approximately $591,000, of which the related party portion will be approximately $157,000. These agreements are under review by our Business Review Committee and reconstituted Board which has curtailed spending on this program until their review is complete and recommendations are made.
Critical Accounting Estimates
There have been no material changes to our critical accounting estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our Annual Report on Form 10-K for the year ended April 30, 2025.
Available Information
Our website is located at www.PharmaCyte.com. In addition, all our filings submitted to the Commission, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all our other reports and statements filed with the Commission are available on the Commission’s web site at www.sec.gov. Such filings are also available for download free of charge on our website. The contents of the website are not, and are not intended to be, incorporated by reference into this Quarterly Report or any other report or document filed with the Commission or furnished by us, and any reference to the websites are intended to be inactive textual references only.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
The information called for by Item 3 is not required for a smaller reporting company.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our Chairman, Chief Executive Officer, and President, as our principal executive officer (“Chief Executive Officer”), and our Chief Financial Officer, as our principal financial officer (“Chief Financial Officer”), evaluated the effectiveness of our “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) promulgated under the Exchange Act. Disclosure controls and procedures are designed to ensure that the information required to be disclosed in the reports that we file or submit to the Commission pursuant to the Exchange Act are recorded, processed, summarized and reported within the period specified by the Commission’s rules and forms and are accumulated and communicated to our management, including our Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosures. Based upon this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of January 31, 2026, certain of our disclosure controls and procedures were not effective due to the material weaknesses in internal control over financial reporting.
Reference should be made to our Form 10-K filed with the Commission on August 11, 2025, for additional information regarding discussion of the effectiveness of the Company’s control and procedures.
| 40 |
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Also, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Changes in Internal Controls over Financial Reporting
There were no changes to our internal control over financial reporting during the nine months ended January 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
In connection with the January 31, 2026 reporting process, management identified two ongoing material weaknesses related to the Company’s internal controls: insufficient segregation of duties of our Chief Financial Officer and insufficient management review controls.
The Certifications of our Chief Executive Officer and Chief Financial Officer required in accordance with Rule 13a-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002 (“Certifications”) are attached to this Quarterly Report. The disclosures set forth in this Item 4 contain information concerning: (i) the evaluation of our disclosure controls and procedures, and changes in internal control over financial reporting, referred to in paragraph 4 of the Certifications; and (ii) material weaknesses in the design or operation of our internal control over financial reporting, referred to in paragraph 5 of the Certifications. The Certifications should be read in conjunction with this Item 4 for a more complete understanding of the matters covered by the Certifications.
| 41 |
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we are subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, we do not believe that the outcome of any pending claims will have a material adverse effect on our financial condition or operating results.
Item 1A. Risk Factors.
You should consider the risks and uncertainties described under Item 1A of Part I of our Annual Report on Form 10-K for the fiscal year ended April 30, 2025, which we filed with the Securities and Exchange Commission on August 11, 2025, together with all other information contained or incorporated by reference in this Quarterly Report on Form 10-Q, when evaluating our business and our prospects. The risks and uncertainties that we face are not limited to those set forth in the Annual Report on 10-K. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business and the trading price of our securities. There are no material changes to the risk factors set forth in Part I, Item 1A, in our Annual Report on Form 10-K for the year ended April 30, 2025, except as described below:
Nasdaq may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions.
On December 1, 2025, we received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying us that for the preceding 30 consecutive business days our Common Stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a grace period of 180 calendar days, or until June 1, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance can be achieved automatically and without further action if the closing bid price of our Common Stock is at or above $1.00 for a minimum of 10 consecutive business days at any time during the 180-day compliance period, in which case Nasdaq will notify us of our compliance and the matter will be closed.
If, however, we do not achieve compliance with the Minimum Bid Price Requirement by June 1, 2026, we may be eligible for additional time to comply. In order to be eligible for such additional time, we will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and must notify Nasdaq in writing of our intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to Nasdaq that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq will provide notice that our Common Stock will be subject to delisting. We would then be entitled to appeal that determination to a Nasdaq hearings panel.
Should we fail to satisfy additional continued listing requirements, such as the corporate governance requirements or the Minimum Bid Price Requirement, Nasdaq may take steps to delist our Common Stock. Such a delisting would likely have a negative effect on the price of our Common Stock, and would impair your ability to sell or purchase our Common Stock when you wish to do so. In the event of a delisting, we would take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our Common Stock, prevent our Common Stock from dropping below Nasdaq’s Minimum Bid Price Requirement or prevent future non-compliance with the Nasdaq’s listing requirements.
| 42 |
If Nasdaq does not maintain the listing of our securities for trading on its exchange, we could face significant material adverse consequences, including:
| · | a limited availability of market quotations for our Common Stock; | |
| · | reduced liquidity for our Common Stock; | |
| · | a determination that our Common Stock is a “penny stock” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; | |
| · | a limited amount of news and analyst coverage; and | |
| · | a decreased ability to issue additional Common Stock or obtain additional financing in the future. |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosure.
Not applicable.
| 43 |
Item 5. Other Information.
During the
three months ended January 31, 2026, no director or officer of the Company
Item 6. Exhibits.
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and included in exhibit 101). |
* Indicates a management contract, compensation plan, or arrangement.
| 44 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned thereunto duly authorized.
PharmaCyte Biotech, Inc.
| March 17, 2026 | By: /s/ Joshua N. Silverman |
| Joshua N. Silverman | |
| Chief Executive Officer | |
| (Principal Executive Officer) | |
| March 17, 2026 | By: /s/ Carlos A. Trujillo |
| Carlos A. Trujillo | |
| Chief Financial Officer | |
| (Principal Financial Officer and Principal Accounting Officer) |
| 45 |